GuidelineDiabetes care2012
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Erratum issued 14 registry-linked trialsAbstract readPractice GuidelineReview
In one paragraph
Guideline in Diabetes care, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 14 registered trials, which are not on this map. Cited by 1,308 papers, 8 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1,308citing papers in PubMed, 8 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 3 Study of the Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Renal Outcomes in Humans With Diabetic Kidney Disease
PMID 20622169PMID 20002084PMID 22691169PMID 21744074PMID 16177002PMID 15664230PMID 14675042PMID 21975753PMID 22608055PMID 22969168PMID 23173142PMID 21537349other papers from this trial
Open the trial in the graphEffect of Metformin Glycinate on Postprandial Lipemia, Glycemic Control and Oxidation Markers in Type 2 Diabetes Patients
Open the trial in the graphA 16-wk, Uni-center, Randomized, Double-blind, Parallel, Phase 3b Trial to Evaluate Efficacy of Saxagliptin + Dapagliflozin vs.Dapagliflozin With Regard to EGP in T2DM With Insufficient Glycemic Control on Metformin+/-Sulfonylurea Therapy
PMID 24463448PMID 9742977PMID 21781152PMID 18726829PMID 25425451PMID 21114605PMID 24947443PMID 23589542PMID 23863067PMID 23992601PMID 21410628PMID 25370334other papers from this trial
Open the trial in the graphA Study of the Effects of Dapagliflozin on Ambulatory Aortic Pressure, Arterial Stiffness and Urine Albumin Excretion in Patients With Type 2 Diabetes
PMID 22411919PMID 24919526PMID 24745924PMID 25054271PMID 12748858PMID 12802026PMID 16306358PMID 17000623PMID 17130190PMID 17934153PMID 18256578PMID 18268136other papers from this trial
Open the trial in the graphA 28-week, Multi-center Randomized, Double-blind, Placebo-controlled Study to Evaluate the Potential of Dapagliflozin Plus Exenatide in Combination With High-dose Intensive Insulin Therapy Compared to Placebo in Obese Insulin-resistant Patients With Type 2 Diabetes Mellitus (Proof-of-concept Study)
PMID 27651331PMID 18613325PMID 24741511PMID 24251534PMID 22608371PMID 22526604PMID 22431673PMID 21307137PMID 20609969PMID 18165348PMID 26213556PMID 11815510other papers from this trial
Open the trial in the graphRandomized Controlled Trial to Assess the Educational Efficacy of a Serious Game for Teaching Insulin Therapy to Primary Care Physicians
Shared Decision Making in Type 2 Diabetes With a Support Decision Tool That Takes Into Account Patient Preferences, Clinical Factors and the Intensity of Treatment: Design of a Cluster Randomised Trial
DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function
A Randomised Controlled Trial of a Duodenal Sleeve Bypass Device (EndoBarrier)Compared With Standard Medical Therapy for the Management of Obese Subjects With Type 2 Diabetes
Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes
Treating Type 2 Diabetes by Reducing Postprandial Glucose Elevations: A Paradigm Shift in Lifestyle Modification
Benefits of Adding Continuous Glucose Monitoring to Glycemic Load, Exercise, and Monitoring of Blood Glucose (GEM) for Adults With Type 2 Diabetes - Phase 2
A Dietary Intervention With Functional Foods Reduce Metabolic Endotoxemia and Attenuates Biochemical Abnormalities in Subjects With Type 2 Diabetes by Modifying the Gut Microbiota.
Metabolic, Pressor and Neuropsychological Effects of Metyrapone Treatment in Patients With Hypercortisolism
Who cites it
1,308 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Behavior change techniques in low-calorie and very low-calorie diet interventions for weight loss: A systematic review with meta-analysis.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Pooled it
- Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review.Journal of diabetes research · 2024Pooled it
- A model-based meta analysis study of sodium glucose co-transporter-2 inhibitors.CPT: pharmacometrics & systems pharmacology · 2023Pooled it
- Major malformations risk following early pregnancy exposure to metformin: a systematic review and meta-analysis.BMJ open diabetes research & care · 2023 · on this mapPooled it
- Pooled it
- Low-carbohydrate versus balanced-carbohydrate diets for reducing weight and cardiovascular risk.The Cochrane database of systematic reviews · 2022Pooled it
- Effects of Yoga on Blood Glucose and Lipid Profile of Type 2 Diabetes Patients Without Complications: A Systematic Review and Meta-Analysis.Frontiers in sports and active living · 2022Pooled it
- Task-sharing interventions for improving control of diabetes in low-income and middle-income countries: a systematic review and meta-analysis.The Lancet. Global health · 2021Pooled it
- Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double-Blind Phase II Trial.Diabetes, obesity & metabolism · 2026Trial
- Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH.BMJ open diabetes research & care · 2026Trial
- Efficacy and Safety of Triple Fixed Dose Combination of Dapagliflozin + Sitagliptin + Metformin IR in Indian Patients with Type 2 Diabetes Mellitus: A Randomized, Phase 3 Study in Comparison with Dual FDC Sitagliptin + Metformin IR.Advances in therapy · 2025Trial
- Impact of Medically Tailored Meals on Clinical Outcomes Among Low-Income Adults with Type 2 Diabetes: A Pilot Randomized Trial.Journal of general internal medicine · 2025Trial
- Fixed dose combination of dapagliflozin, glimepiride and extended-release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase III, open label, randomized clinical study in India.Diabetes, obesity & metabolism · 2025Trial
- Factors contributing to the clinical effectiveness of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus.Journal of diabetes investigation · 2024Trial
- Randomized trial of an integrated care intervention among Latino adults: Sustained effects on diabetes management.Translational behavioral medicine · 2024Trial
- Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial.Diabetes & metabolism journal · 2023Trial
- Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations.Advances in therapy · 2023Trial
- HbA1c as a shared treatment goal in type 2 diabetes? A secondary analysis of the DEBATE trial.BMC primary care · 2023Trial
- Attrition and social vulnerability during 2-year-long structured care in type 2 diabetes, the ERMIES randomized controlled trial.BMC endocrine disorders · 2022Trial
- The impact of lifestyle intervention on left atrial function in type 2 diabetes: results from the DIASTOLIC study.The international journal of cardiovascular imaging · 2022Trial
1,248 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
12 authors.
Silvio E InzucchiSection of Endocrinology, Yale University School of Medicine, New Haven, Connecticut, USA. silvio.inzucchi@yale.edu
Richard M Bergenstal
John B Buse
Michaela Diamant
Ele Ferrannini
Michael Nauck
Anne L Peters
Apostolos Tsapas
Richard Wender
David R Matthews
American Diabetes Association (ADA)
European Association for the Study of Diabetes (EASD)
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Patient-Centered CareAge FactorsAlgorithmsCardiovascular DiseasesDiabetes Mellitus, Type 2EuropeFemaleGlycated HemoglobinHumansHyperglycemiaHypoglycemic AgentsKidney DiseasesLiver DiseasesMaleRisk FactorsUnited StatesGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic Agents
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT01847313ClinicalTrials.gov
NCT02064881ClinicalTrials.gov
NCT02613897ClinicalTrials.gov
NCT02887677ClinicalTrials.gov
NCT03419624ClinicalTrials.gov
NCT01759953ClinicalTrials.gov
and 8 more above
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.